His study in Cognitive impairment extends to Disease with its themes. His research on Cognitive impairment often connects related topics like Disease. As part of his studies on Pathology, Gil D. Rabinovici frequently links adjacent subjects like Amyloid (mycology). Gil D. Rabinovici combines topics linked to Pathology with his work on Amyloid (mycology). Gil D. Rabinovici merges many fields, such as Dementia and Posterior cortical atrophy, in his writings. Gil D. Rabinovici performs integrative Posterior cortical atrophy and Dementia research in his work. His work in Neuroscience is not limited to one particular discipline; it also encompasses Hippocampus. Gil D. Rabinovici frequently studies issues relating to Neuroscience and Hippocampus. In his papers, he integrates diverse fields, such as Alzheimer's disease and Primary progressive aphasia.
His Frontotemporal dementia research is covered under the topics of Frontotemporal lobar degeneration and Primary progressive aphasia. His work often combines Primary progressive aphasia and Frontotemporal dementia studies. His research combines Progressive supranuclear palsy and Disease. His Progressive supranuclear palsy study frequently draws parallels with other fields, such as Disease. In most of his Pathology studies, his work intersects topics such as Amyloid (mycology). Many of his studies involve connections with topics such as Pathology and Amyloid (mycology). His Dementia study typically links adjacent topics like Cognitive decline. His Cognitive decline study frequently draws connections to other fields, such as Dementia. Gil D. Rabinovici conducted interdisciplinary study in his works that combined Neuroscience and Neuroimaging.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Sandip Ray;Markus Britschgi;Charles Herbert;Yoshiko Takeda-Uchimura.
Nature Medicine (2007)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens.
Alzheimers & Dementia (2016)
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Günter U Höglinger;Gesine Respondek;Maria Stamelou;Carolin Kurz.
Movement Disorders (2017)
Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease
Juan Zhou;Michael D. Greicius;Efstathios D. Gennatas;Matthew E. Growdon.
PET Imaging of Tau Deposition in the Aging Human Brain
Michael Schöll;Michael Schöll;Samuel N. Lockhart;Daniel R. Schonhaut;James P. O’Neil.
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Rik Ossenkoppele;Rik Ossenkoppele;Rik Ossenkoppele;Daniel R. Schonhaut;Daniel R. Schonhaut;Michael Schöll;Michael Schöll;Samuel N. Lockhart.
Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects
E. C. Mormino;J. T. Kluth;C. M. Madison;G. D. Rabinovici;G. D. Rabinovici;G. D. Rabinovici.
Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.
Gil D. Rabinovici;Bruce L. Miller.
CNS Drugs (2010)
Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease
Keith A. Vossel;Alexander J. Beagle;Gil D. Rabinovici;Huidy Shu;Huidy Shu.
JAMA Neurology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: